Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which hormone best prevents endometrioma return after surgery?

NCT ID NCT07519213

Disease control Sponsor: Guangdong Women and Children Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study looked at over 1,100 women who had surgery for ovarian endometriomas (cysts caused by endometriosis) and then took one of four hormonal treatments to prevent recurrence. The goal was to see which treatment—birth control pills, GnRH agonists, dienogest, or dydrogesterone—was most effective at stopping new cysts from forming within two years. Results could help doctors choose the best post-surgery hormone therapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hormonal treatments (combined oral contraceptives, GnRH agonists, dienogest, or dydrogesterone)
What this could lead to
If this study shows one hormonal regimen works better, it could help doctors choose the best option to prevent endometriomas from coming back after surgery.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be influenced by unmeasured factors. The findings need confirmation in prospective studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,121 people

The number who actually took part.

Started

Sep 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with ovarian endometrioma who underwent conservative surgery at a single study center and subsequently received postoperative hormonal therapy in routine clinical practice.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients who underwent conservative surgery for ovarian endometrioma at the study center. * Initiation of one postoperative hormonal regimen within 1 month after surgery. * Continuous use of the same single hormonal regimen for at least 6 months after surgery. * Availability of clinical records and postoperative follow-up data for assessment of study outcomes. Exclusion Criteria: * Failure to initiate postoperative hormonal therapy within 1 month after surgery. * Discontinuation of the postoperative hormonal regimen before 6 months. * Use of sequential or multiple postoperative hormonal therapies during the initial treatment period. * Incomplete clinical records or insufficient follow-up data for evaluation of recurrence.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometriosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometriosis ovarian endometriosis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometriosis Ovarian endometrioma

Contacts and locations

Locations

  • Guangdong Women and Children Hospital

    Guangzhou, Guangdong, 511400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.